Gemtuzumab ozogamicin for relapsed or primary refractory acute myeloid leukemia in children—the Polish Pediatric Leukemia and Lymphoma Study Group experience

Gemtuzumab ozogamicin for relapsed or primary refractory acute myeloid leukemia in children—the Polish Pediatric Leukemia and Lymphoma Study Group experience

BackgroundGemtuzumab ozogamicin (GO), one of the first targeted drugs used in oncology, consists of an anti-cluster of differentiation 33 (CD33) monoclonal antibody bound to a derivative of cytotoxic calicheamicin. After the drug withdrawn in 2010 due to a significantly higher rate of early deaths,...

Descrizione completa

Dettagli Bibliografici
Autori principali: Katarzyna Pawinska-Wasikowska, Malgorzata Czogala, Szymon Skoczen, Marta Surman, Monika Rygielska, Teofila Ksiazek, Agnieszka Pac, Aleksandra Wieczorek, Jolanta Skalska-Sadowska, Magdalena Samborska, Jacek Wachowiak, Radoslaw Chaber, Renata Tomaszewska, Tomasz Szczepanski, Karolina Zielezinska, Tomasz Urasinski, Malgorzata Moj-Hackemer, Krzysztof Kalwak, Marta Kozlowska, Ninela Irga-Jaworska, Walentyna Balwierz, Karolina Bukowska-Strakova
Natura: Articolo
Lingua:English
Pubblicazione: Frontiers Media S.A. 2023-12-01
Serie:Frontiers in Immunology
Soggetti:
acute myeloid leukemia
gemtuzumab ozogamicin
relapse
refractory
children
immunotherapy
Accesso online:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1268993/full

Accesso online

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1268993/full

Documenti analoghi